Ensoma /en’sōmə/ is derived from the Greek phrase “en soma,” meaning in the body. We develop one-time in vivo treatments that precisely engineer any or all blood and immune cells to cure diseases from within. We have a bigger, bolder vision for genomic medicine: treatments as versatile, precise, and far-reaching as the body’s own cells. Our team takes inspired action towards pushing beyond today’s possible with the goal of delivering a one-time, off-the-shelf treatment to patients everywhere.

RIT Capital Partners

5AM Ventures

Alexandria Venture Investments

Cormorant Asset Management

F-Prime Capital

SymBiosis LLC

Takeda Ventures

Viking Global Investors

Bioluminescence Ventures

Delos Capital

Kite Pharma

Qatar Investment Authority

Catalio Capital Management

Solasta Ventures

Fred Hutchinson

Mirae Asset

Ensoma

Takeda is a multinational pharmaceutical company that has a wide-ranging partnership with Ensoma, covering up to five experimental programs in the gene therapy space.

Takeda

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing in vivo gene therapies for various genetic disorders.

BioMarin Pharmaceutical Inc.

Intellia Therapeutics, Inc. is a leading biotechnology company specializing in in vivo gene therapy and CRISPR/Cas9 technology.

Intellia Therapeutics, Inc.

CRISPR Therapeutics is a biopharmaceutical company focused on developing transformative gene-based medicines using CRISPR/Cas9 technology for in vivo applications.

CRISPR Therapeutics

Sangamo Therapeutics, Inc. is a biotechnology company specializing in the development of in vivo gene therapies and genome editing technologies.

Sangamo Therapeutics, Inc.

Ensoma is a biotechnology company focused on developing in vivo engineered cellular medicines. The company leverages its proprietary platform to create transformative gene therapies for patients with severe genetic disorders.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 15, 2024 12:34 PM	cb7c15ad
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 15, 2024 12:34 PM	8adb5fa2
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ENSOMA

Ensoma